Halozyme Therapeutics (HALO) Misses Q3 EPS by 5c

November 12, 2019 4:32 PM

Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.17), $0.05 worse than the analyst estimate of ($0.12). Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found